In 2022, it is really difficult to turn around the medical fund of Julun. The epidemic that began in 2020 was followed by the dividend of the medical industry, which really made the medical fund a fire. And Glenn also took advantage of this east wind to ascend to the throne of Yaoshen. The medical bonus accompanying the epidemic caused the medical and health funds in China and Europe to skyrocket. It can be said that everyone in the fund circle knew it at that time.

Fall into the altar, but people are not as good as the sky, and flowers are not as good as the sky. The rapid rise of medical funds is also accompanied by crisis. Since the second half of last year, with the adjustment of the medical industry, this fund under Gü len began to fall sharply, which was much higher than the industry index, and the decline of the same type of fund products was not so great. Perhaps in this case, many people think that the scale of this China-Europe medical fund under Gulen will definitely shrink, but the result is just the opposite.

With the net value of the fund plummeting, the scale of this fund is getting bigger and bigger, and there has been a phenomenon of buying down. Maybe it's because everyone thinks that the medical fund has almost fallen and it's time to rebound. But the fact is that the more you sell, the lower you fall, and there is no low point. At present, the scale of funds owned by Gü len has surpassed that of Zhang Kun, the first public offering brother, and reached the scale of 1000 billion.

Last year, the scale of China-Europe medical and health mixed fund continued to expand, and citizens expressed their support for this medical goddess with real money. But how far can such support go if the benefits are not seen for a long time?

Who is behind this scene from climbing to falling from the altar? Judging from Glenn's position, she mainly holds leading companies in the medical industry. WuXi PharmaTech, in particular, saw its share price reach 172 yuan last year, and now it has reached 83.07 yuan, which can be said that it has been halved. In this case, Gulen is still optimistic about the company's prospects, or has not had time to change positions. It is normal for top fund managers to be questioned by the market because of their sharp withdrawal from performance, depending on whether they can get out of adversity.